Clinical Research Directory
Browse clinical research sites, groups, and studies.
Acupoint Application for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer
Sponsor: Xiu Huang
Summary
This single-center, randomized, controlled study evaluates whether acupoint application added to standard 5-HT3 receptor antagonist anti-nausea medication improves control of chemotherapy-induced nausea and vomiting in adults with lung cancer receiving first-line platinum-based chemotherapy. Participants will be randomly assigned to receive either acupoint application plus a 5-HT3 receptor antagonist or the 5-HT3 receptor antagonist alone for one chemotherapy cycle. The study will compare complete control of delayed nausea and vomiting between the two groups.
Official title: Acupoint Application Combined With 5-HT3 Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: A Single-Center, Randomized, Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-07-15
Completion Date
2026-10-15
Last Updated
2026-08-17
Healthy Volunteers
No
Interventions
5-HT3 receptor antagonist (e.g., ondansetron)
Standard antiemetic prophylaxis for chemotherapy-induced nausea and vomiting.
Acupoint application
Herbal plaster applied to selected acupoints to alleviate chemotherapy-induced nausea and vomiting.
Locations (1)
The Affiliated Yongchuan Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China